| 1 |
Neubauer A, Zucca E. Gastrointestinal tract lymphomas. In: Cavali F, Stein H, Zucca E, eds. Extranodal Lymphomas Pathology and Management. London: Informa Health Care, 2008:233-243.
|
| 2 |
Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
DOI
ScienceOn
|
| 3 |
Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000;96:410-419.
|
| 4 |
Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007;56:1685-1687.
DOI
ScienceOn
|
| 5 |
Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086-1093.
DOI
ScienceOn
|
| 6 |
Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024.
DOI
ScienceOn
|
| 7 |
Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400.
DOI
|
| 8 |
Nakamura S, Yao T, Aoyagi K, Iida M, Fujishima M, Tsuneyoshi M. Helicobacter pylori and primary gastric lymphoma: a histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997;79:3-11.
DOI
ScienceOn
|
| 9 |
Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176.
DOI
ScienceOn
|
| 10 |
Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report: gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-758.
DOI
ScienceOn
|
| 11 |
National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines V.3.2012-Non-Hodgkin's lymphomas [Internet]. Fort Washington (PA): National Comprehensive Cancer Network, c2012. Available from: http://www.nccn.org/index.asp.
|
| 12 |
Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 2006;107:2770-2778.
DOI
ScienceOn
|
| 13 |
Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001;48:297-303.
DOI
ScienceOn
|
| 14 |
Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999;131:88-95.
DOI
ScienceOn
|
| 15 |
Raderer M, Streubel B, Wohrer S, Hafner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006;55:616-618.
DOI
ScienceOn
|
| 16 |
Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.
DOI
ScienceOn
|
| 17 |
Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosaassociated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
DOI
|
| 18 |
Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061-5066.
DOI
ScienceOn
|
| 19 |
Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178:122-127.
DOI
ScienceOn
|
| 20 |
Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009;144:367-375.
DOI
ScienceOn
|
| 21 |
Hussell T, Isaacson PG, Spencer J. Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro. J Pathol 1993;169:221-227.
DOI
|
| 22 |
Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877.
DOI
ScienceOn
|
| 23 |
Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-1723.
DOI
ScienceOn
|
| 24 |
Wohrer S, Raderer M, Kaufmann H, et al. Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. Onkologie 2005;28:73-78.
DOI
ScienceOn
|
| 25 |
Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006;70:411-417.
DOI
ScienceOn
|
| 26 |
Levy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma 2010;51:284-290.
DOI
ScienceOn
|
| 27 |
Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-5217.
DOI
ScienceOn
|
| 28 |
Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653.
DOI
ScienceOn
|
| 29 |
Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) Study. Ann Hematol 2012;91:543-551.
DOI
ScienceOn
|
| 30 |
Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:6370-6378.
DOI
ScienceOn
|
| 31 |
Troch M, Jonak C, Mullauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009;94:738-742.
DOI
ScienceOn
|
| 32 |
Stathis A, Bertoni F, Zucca E. Treatment of gastric marginal zone lymphoma of MALT type. Expert Opin Pharmacother 2010;11:2141-2152.
DOI
ScienceOn
|
webmaster
